Virax Biolabs Group (VRAX) Competitors $1.01 +0.01 (+1.00%) As of 10:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRAX vs. UPXI, EQ, NKGN, PRPH, ME, IBIO, SYBX, MRKR, NXTC, and AYTUShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Upexi (UPXI), Equillium (EQ), NKGen Biotech (NKGN), ProPhase Labs (PRPH), 23andMe (ME), iBio (IBIO), Synlogic (SYBX), Marker Therapeutics (MRKR), NextCure (NXTC), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Upexi Equillium NKGen Biotech ProPhase Labs 23andMe iBio Synlogic Marker Therapeutics NextCure Aytu BioPharma Virax Biolabs Group (NASDAQ:VRAX) and Upexi (NASDAQ:UPXI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk. Which has more volatility and risk, VRAX or UPXI? Virax Biolabs Group has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Upexi has a beta of -0.27, indicating that its stock price is 127% less volatile than the S&P 500. Does the media refer more to VRAX or UPXI? In the previous week, Upexi had 1 more articles in the media than Virax Biolabs Group. MarketBeat recorded 1 mentions for Upexi and 0 mentions for Virax Biolabs Group. Upexi's average media sentiment score of 0.34 beat Virax Biolabs Group's score of 0.00 indicating that Upexi is being referred to more favorably in the news media. Company Overall Sentiment Virax Biolabs Group Neutral Upexi Neutral Do insiders & institutionals believe in VRAX or UPXI? 8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 31.6% of Upexi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has stronger valuation & earnings, VRAX or UPXI? Virax Biolabs Group has higher earnings, but lower revenue than Upexi. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirax Biolabs Group$84.87K38.47-$6.73MN/AN/AUpexi$16.56M1.04-$23.66MN/AN/A Is VRAX or UPXI more profitable? Company Net Margins Return on Equity Return on Assets Virax Biolabs GroupN/A N/A N/A Upexi N/A N/A N/A Do analysts rate VRAX or UPXI? Virax Biolabs Group presently has a consensus price target of $3.00, suggesting a potential upside of 197.03%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe Virax Biolabs Group is more favorable than Upexi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Upexi 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor VRAX or UPXI? Upexi received 2 more outperform votes than Virax Biolabs Group when rated by MarketBeat users. However, 100.00% of users gave Virax Biolabs Group an outperform vote while only 42.86% of users gave Upexi an outperform vote. CompanyUnderperformOutperformVirax Biolabs GroupOutperform Votes1100.00% Underperform VotesNo VotesUpexiOutperform Votes342.86% Underperform Votes457.14% SummaryVirax Biolabs Group beats Upexi on 9 of the 13 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.27M$2.59B$5.31B$8.28BDividend YieldN/A0.73%5.20%4.10%P/E RatioN/A7.4026.7319.58Price / Sales38.4735.27387.44119.65Price / CashN/A15.7538.2534.62Price / Book0.515.426.744.47Net Income-$6.73M-$65.73M$3.23B$248.22M7 Day Performance-6.48%-0.82%-0.05%-1.32%1 Month Performance-0.98%-0.04%8.51%10.73%1 Year Performance21.25%-15.96%18.25%8.40% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group2.904 of 5 stars$1.01+1.0%$3.00+197.0%+18.7%$3.27M$84,872.000.005UPXIUpexi0.7259 of 5 stars$9.64-5.4%N/A+45.1%$13.75M$18.63M0.00130News CoverageEarnings ReportEQEquillium2.6089 of 5 stars$0.38+2.7%$3.00+681.3%-72.3%$13.72M$41.10M-2.7440Gap DownNKGNNKGen BiotechN/A$0.30-14.2%N/A-85.4%$13.48M$80,000.00-0.06N/APositive NewsGap UpPRPHProPhase Labs1.8266 of 5 stars$0.32-17.2%N/A-94.1%$13.43M$6.77M-0.25130Earnings ReportGap DownME23andMeN/A$0.50-35.3%N/A-95.2%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeIBIOiBio1.1488 of 5 stars$0.800.0%$4.30+438.0%-64.4%$13.20M$375,000.000.00100SYBXSynlogicN/A$1.10+1.9%N/A-30.4%$12.87M$8,000.00-0.2680Upcoming EarningsMRKRMarker Therapeutics4.0913 of 5 stars$1.13+1.8%$13.17+1,065.2%-71.3%$12.79M$6.59M-0.8560Positive NewsNXTCNextCure3.9414 of 5 stars$0.45+2.7%$3.50+677.8%-69.3%$12.62MN/A-0.2290Positive NewsGap DownAYTUAytu BioPharma1.572 of 5 stars$2.00-6.1%N/A-35.3%$12.34M$77.23M-1.38160High Trading Volume Related Companies and Tools Related Companies Upexi Competitors Equillium Competitors NKGen Biotech Competitors ProPhase Labs Competitors 23andMe Competitors iBio Competitors Synlogic Competitors Marker Therapeutics Competitors NextCure Competitors Aytu BioPharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRAX) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRAX Stock Free VRAX Stock Alerts